



FMNL2 regulates gliovascular interactions and is associated with vascular risk factors and cerebrovascular pathology in Alzheimer's disease

Annie J. Lee^{1,2,3} · Neha S. Raghavan^{1,3} · Prabesh Bhattarai^{1,3,4} · Tohid Siddiqui⁴ · Sanjeev Sariya^{1,3} · Dolly Reyes-Dumeyer^{1,2,3} · Xena E. Flowers¹ · Sarah A. L. Cardoso¹ · Philip L. De Jager^{1,3} · David A. Bennett⁵ · Julie A. Schneider⁵ · Vilas Menon^{1,3} · Yanling Wang⁵ · Rafael A. Lantigua^{1,6} · Martin Medrano¹⁰ · Diones Rivera^{11,12} · Ivonne Z. Jiménez-Velázquez⁹ · Walter A. Kukull⁸ · Adam M. Brickman^{1,2,3} · Jennifer J. Manly^{1,2,3} · Giuseppe Tosto^{1,2,3} · Caghan Kizil^{1,3,4} · Badri N. Vardarajan^{1,2,3} · Richard Mayeux^{1,2,3,7}

Received: 2 March 2022 / Revised: 3 May 2022 / Accepted: 4 May 2022
© The Author(s) 2022

Abstract

Alzheimer's disease (AD) has been associated with cardiovascular and cerebrovascular risk factors (CVRFs) during middle age and later and is frequently accompanied by cerebrovascular pathology at death. An interaction between CVRFs and genetic variants might explain the pathogenesis. Genome-wide, gene by CVRF interaction analyses for AD, in 6568 patients and 8101 controls identified *FMNL2* ($p = 6.6 \times 10^{-7}$). A significant increase in *FMNL2* expression was observed in the brains of patients with brain infarcts and AD pathology and was associated with amyloid and phosphorylated tau deposition. *FMNL2* was also prominent in astroglia in AD among those with cerebrovascular pathology. Amyloid toxicity in zebrafish increased *fmdl2a* expression in astroglia with detachment of astroglial end feet from blood vessels. Knockdown of *fmdl2a* prevented gliovascular remodeling, reduced microglial activity and enhanced amyloidosis. APP/PS1dE9 AD mice also displayed increased *Fmdl2* expression and reduced the gliovascular contacts independent of the gliotic response. Based on this work, we propose that *FMNL2* regulates pathology-dependent plasticity of the blood–brain-barrier by controlling gliovascular interactions and stimulating the clearance of extracellular aggregates. Therefore, in AD cerebrovascular risk factors promote cerebrovascular pathology which in turn, interacts with *FMNL2* altering the normal astroglial-vascular mechanisms underlying the clearance of amyloid and tau increasing their deposition in brain.

Keywords Alzheimer's disease · Cerebrovascular risk factors · GWAS · *FMNL2* · Zebrafish · Human · Mouse · Gliovascular interaction · Neurovascular unit · Blood–brain-barrier

Introduction

Alzheimer's disease (AD) affects more than 6.2 million people in the United States and approximately 24 million worldwide. Neuropathological studies indicate that in AD, the hallmark findings of neuritic plaques and neurofibrillary tangles can frequently be accompanied by varying degrees of cerebrovascular disease in up to 70% of patients [4, 16,

44, 74]. Amyloid β in blood vessels, as in cerebral amyloid angiopathy, reduces cerebral blood flow and is present in most patients with AD. However, as cardio and cerebrovascular risk factors (CVRFs) increase in the elderly, accompanied by inflammation, cytokine release, endothelial dysfunction and arterial stiffening in brain [81]. Cholesterol laden macrophages accumulate in vessel walls also decreasing blood flow. The increase in atherosclerosis in the intracerebral arteries [55] and capillaries leads to microinfarcts in the hippocampus contributing to cognitive decline [34].

The relationship between CVRFs such as hypertension [78], body mass index [33, 57], diabetes [22, 59] and coronary heart disease [42, 65] and AD is well known, but there has been limited mechanistic evidence directly linking these vascular risk factors in AD to the presence of

Caghan Kizil, Badri N. Vardarajan and Richard Mayeux contributed equally to the manuscript.

✉ Richard Mayeux
rpm2@cumc.columbia.edu

Extended author information available on the last page of the article

ischemic microvascular pathology. Each of these vascular factors has the capacity to impair the blood–brain barrier and glio-vascular units. Arterial pulses and flow are required for glymphatic clearance of molecules including amyloid β [42, 65, 86]. Jagust and colleagues argued that cerebrovascular disease contributed to AD by perturbing the amyloid β pathway in addition to causing neurodegeneration [38]. However, the effects reported in epidemiological studies of the association between CVRFs and AD are inconsistent, increasing AD risk in some studies [86], but in others showing protection against AD [64, 86]. The relationship between vascular risk factors and cerebrovascular pathology in AD could simply be the result of aging, the stage of the disease or a coincidental occurrence. An alternative explanation is that an unidentified interaction between genetic variants and vascular risk factors leading to cerebrovascular pathology in AD brain may contribute to disease pathogenesis.

APOE, *CLU*, *ABCA7*, and *SORL1*, typically associated with immune mechanisms in AD, are also part of the lipid metabolism pathway providing evidence for a putative molecular relationship. In fact, *ABCA7* and *SORL1* have been associated with brain infarcts [31]. Using summary statistics from multiple genome-wide associations studies (GWAS), a recent study detected evidence of pleiotropy between vascular risk factors and AD [17]. Another investigation [88] found shared genetic contribution to AD and small vessel disease. Despite the possible associations between genes, vascular factors and AD, there has been no unbiased genome-wide study of genes or genetic loci to investigate the interaction between cerebrovascular risk factors, cerebrovascular pathology, and AD.

Previously, we observed that the cumulative burden of vascular risk factors increased the association with AD risk [58, 70] compared with a single risk factor. Therefore, in this investigation, a dimensionality reduction of four common cardiovascular risk factors frequently associated with cerebrovascular disease and with AD: hypertension,

heart disease, diabetes, and body mass index (BMI), was employed to create a vascular risk factor burden score. To augment the sample size, we included data from five different cohorts representing different ethnic groups, facilitating the interaction analyses.

Materials and methods

Clinical studies

Participants

Participants were from the following studies: Washington Heights–Inwood Columbia Aging Project (WHICAP), Estudio Familiar de Influencia Genética en Alzheimer (EFIGA), the National Alzheimer’s Coordinating Center (NACC), and the Religious Orders Study and Rush Memory and Aging Project (ROSMAP) (Table 1). WHICAP is a multiethnic, prospective, community-based cohort study of aging and dementia in Medicare recipients 65 years and older residing in northern Manhattan. A detailed description of the study was previously published [83]. Participants are initially recruited as nondemented elderly and were non-Hispanic white, African American or Caribbean Hispanic. A consensus diagnosis was derived for each participant by experienced clinicians based on NINCDS-ADRDA criteria for possible, probable, or definite AD (moderate or high likelihood of neuropathological criteria for AD) [61]. Recruitment for the EFIGA began in 1998, to study the genetic architecture of AD in the Caribbean Hispanic population. Patients with familial AD were recruited and if a sibling of the proband had dementia, all other living siblings and available relatives underwent evaluation. Cases were defined as any individual meeting NINCDS-ADRDA criteria for probable or possible AD. Details of the study have previously been reported [90]. NACC collects, organizes, and maintains

Table 1 Participant demographics included

	ROSMAP	WHICAP African-Americans	WHICAP Whites	Caribbean Hispanics	NACC
<i>N</i>	1424	978	851	3404	8012
Ethnicity/race	Non-Hispanic whites	African-Americans	Non-Hispanic whites	Caribbean Hispanics	Non-Hispanic whites
% Women	70%	72%	60%	68%	56%
% AD	34%	33%	21%	51%	48%
Mean BMI (s.d.)	26.5 (5.51)	28.21 (6.17)	26.59 (5.07)	26.89 (5.26)	26.24 (4.69)
% hypertension	62%	82%	66%	76%	62%
% Heart disease	22%	39%	44%	23%	40%
% diabetes	21%	29%	15%	31%	12%
Mean age (s.d.)	85.93 (6.87)	80 (7.24)	81.01 (7.33)	75	78.42 (7.69)

s.d. standard deviation, *ROSMAP* Religious Orders Study and Rush Memory and Aging Project, *NACC* National Alzheimer’s Disease Coordinating Center, *WHICAP* Washington Heights, Hamilton Heights, Inwood Columbia Aging Project

phenotype information from National Institute on Aging (NIA) Alzheimer's Disease Centers (ADCs). Genetic data were provided from wave 1–10 of the ADC genotyping. The Uniform Data Set (UDS) is made up of standardized clinical evaluations and diagnoses along with demographic information. Details on the UDS and NACC database can be found at <http://www.alz.washington.edu/>. ROSMAP are two harmonized longitudinal studies enrolling older adults without dementia: The Religious Orders Study and the Memory and Aging Project (ROSMAP). Details of the ROSMAP studies have been described elsewhere [9, 27]. Only participants 65 years of age or older, that had one or more in person clinical assessments and data concerning four vascular risk factors: any heart disease, hypertension, BMI, and diabetes were included.

Cerebrovascular Risk Factors Score

Self-reported data from each participant were recorded as a binary indicator (Yes-Ever Had or No-Never Had) for heart disease, hypertension, and diabetes. The self-reported of vascular risk factors has reasonable reliability and validity [45]. Details on heart conditions varied between groups, so report of any heart disease qualified as presence of heart disease in this study. A quantitative variable was recorded for body mass index (BMI) from the last visit. The PCAMix package [20] computes principal components (PCs) in a mixture of quantitative and qualitative data, and was used to summarize the cardiovascular risk factors into one summary score by computing PCs from the four cerebrovascular variables. The goal of the dimensionality reduction was to capture the greatest amount of variance accounted for by the four cerebrovascular risk factors, and thus each participant's values from the first principal component from each of the cohorts was used as their vascular risk factor score (CVRF score).

Genotyping

Genotyping was performed on different platforms separately for each study cohort. Data from all cohorts underwent quality control (QC). For African American and white, non-Hispanics WHICAP participants, variants with missing rate greater than 5%, out of Hardy–Weinberg equilibrium ($p < 1 \times 10^{-6}$), or with less than 1% minor allele frequency (MAF) were removed. Participants were excluded if they were missing more than 2% of variants present in the overall cohort. Following quality control (QC), participants were imputed separately based on self-reported ethnicity. Imputation was performed using the HRC r1.1.2016 reference panel and SHAPEIT phasing on the Michigan Imputation Server [26]. Data from the WHICAP Caribbean Hispanics and EFIGA Caribbean Hispanics underwent QC and imputation

in seven batches that included participants from both studies, consistent with the genotyping batch. Variants with missing rate greater than 5%, $MAF \leq 1\%$, out of Hardy–Weinberg equilibrium ($p < 1 \times 10^{-6}$) were removed. Samples with missing call rate greater than 5% were excluded. SHAPEIT2 [28] was used for phasing and IMPUTE2 was used for imputation with the HRC r1.1.2016 reference panel.

Quality control and imputation details for the ROSMAP have been reported previously [4]. Briefly, variants missing in more than 5%, $MAF \leq 1\%$, out of Hardy–Weinberg equilibrium ($p > 0.001$), and a p value of mishap test $< 1 \times 10^{-9}$ were removed. Imputation was performed using the HRC r1.1.2016 reference panel of Caucasian ancestry and Eagle v2.3 phasing. ADC genotype data from waves 1–10 underwent QC by the Alzheimer's Disease Genetic Consortium as described previously [52]. Imputation was performed on the Michigan Imputation Server individually for each of the cohorts including all ethnicities of the Haplotype Reference Consortium (HRC) 1.1 reference panel. EAGLE was used for phasing and Minimac3 was used for imputation.

NACC and ROSMAP cohorts included only participants that self-reported as non-Hispanic White. For all cohorts, post-imputation genotype data were filtered for imputation quality ($R^2 > 0.8$) and minor allele frequency ($> 1\%$). KING[60] was used to perform multidimensional scaling (MDS) to identify population substructure within each cohort. Participants more than six standard deviations from the mean within cohort in the first three calculated MDS components were removed from analysis.

Statistical Analyses

Study design and analyses are described in Supplementary Fig. 1, online resource. Differences in allele frequency were present across ethnic groups, thus we performed genome-wide gene-CVRF score interaction analysis independently in each cohort and summarized the results in a meta-analysis to improve analysis power and results interpretability. Gene-based tests were performed using the adaptive gene-environment interaction (aGE) test [20]. Independently, we validated the results using an alternative method implemented in the gene-environment set association test (GESAT) [56]. Both tests allowed for gene-based analyses with an interaction between the vascular risk factor variable and multiple variants within a gene. GESAT uses a variance component test while, aGE combines variance-component and burden tests to maximize power across broader association patterns. We observed that aGE controls the type I error rate in the presence of many neutral variants, and the power is resilient to the inclusion of neutral variants [20]. Therefore, we used the aGE to test for the genes that interacted with CVRFs to alter AD risk. Additionally, we used GESAT to confirm the robustness of statistically significant results reported

from the aGE. Covariates included in the model were age at diagnosis for AD and age at last visit for the unaffected participants, sex, and the first three principal components to adjust for population substructure. We analyzed genes with a minimum of two variants with allele frequency greater than 0.01 in the gene-based test. The aGE R package and GESAT functions in the iSKAT R package were performed with default settings. Both tests only export *p* value of testing the gene-CVRF score interaction term. We combined the results in a meta-analysis using weighted sum of Z-scores method through METAL [96]. The *p* value of the interaction term in each cohort was first converted into signed Z-score and then calculated as the weighted mean of the Z-scores, with square-root of the sample size from each cohort as weights.

Individual SNPs were tested for CVRF interactions within each gene when a significant gene by vascular risk factors interaction was found. The SNP by CVRF interaction test was performed in each cohort for all SNPs within candidate genes by fitting a logistic regression for AD as the outcome and testing for the interaction term of SNP by CVRF score. The interaction tests were adjusted for the main genetic effect and the CVRF score as covariates in all models, in addition to age, sex, and the first three principal components. The models were tested with additive coding for the SNPs. For models used in the NACC cohort, batch effects were included as covariates because genotyping from ten waves were imputed separately. The results were then combined in a meta-analysis using inverse-variance weighted average method through METAL [96] by calculating the weighted mean of the SNP-CVRF interaction effect sizes, with the inverse variance from each cohort as weights.

Results were shown for SNPs and genes present in at least 10,000 participants. Statistical significance was set at $p = 5 \times 10^{-6}$ for the genome-wide gene-based tests and used the false discovery rate (FDR) adjusted *p* value or Bonferroni correction for the number of genes tested.

RNA expression analysis

As shown in Table 3, we performed association analyses of pathologically diagnosed AD using the multi-region brain transcriptomes from ROSMAP [7–9] and a replication analysis was performed using the transcriptomes from Mount Sinai Medical Center [94] and Mayo Clinic Brain Banks [2]. A logistic regression was fitted for pathological AD as the outcome while adjusting for age, sex, and processing factors. The bulk RNA-sequencing (RNA-Seq) transcriptomic profiles in ROSMAP were accessed from three brain regions—the dorsolateral prefrontal cortex (DLPFC) in 1,092 individuals, the posterior cingulate cortex (PCC) in 661 individuals and the anterior caudate (AC) in 731 individuals. For the MSBB tissues, the transcriptomic profiles were accessed from four brain regions—the frontal pole (BM10) in 214

individuals, the superior temporal gyrus (BM22) in 191 individuals, the parahippocampal gyrus (BM36) in 161 individuals, the inferior frontal gyrus (BM44) in 186 individuals. For the Mayo Clinic brain tissues, the transcriptomic profiles were accessed from the temporal cortex (TCX) in 261 individuals and the cerebellum (CBE) in 262 individuals.

RNA sequencing data in ROSMAP was generated in multiple batches from different sequencing centers and experimental protocols. RNA sequencing of dorsolateral prefrontal cortex (DLPFC) was first done in 10 batches for 739 subjects at the Broad Institute. Subsequently, 124 subjects in 2 batches were sequenced at the New York Genome Center. Moreover, 229 samples in a single batch were sequenced at the Rush Alzheimer's Disease Center. A detailed description of the study was previously published [101]. RNA sequencing of anterior caudate (AC) was done in 76 subjects in a single batch at the Broad Institute using the Illumina TruSeq method, as described above in DLPFC. Subsequently, 655 subjects in 2 batches were sequenced at the New York Genome Center using the same experimental protocols described in DLPFC. RNA sequencing of posterior cingulate cortex (PCC) was done in 79 subjects in a single batch at the Broad Institute using the Illumina TruSeq method. Subsequently, 487 subjects in 2 batches were sequenced at the New York Genome Center and 95 subjects in a single batch were sequenced at the Rush Alzheimer's Disease Center. The experimental protocols of each sequencing center are same as described in DLPFC.

Each brain region was pre-processed separately. We used gene-level transcription values derived from the RNA sequencing data. The counts values were used to measure the gene expression levels and subsequently normalized using Trimmed means of M-values (TMM) to create a frozen dataset that are available on Synapse (Synapse: syn25741873). Outlier samples were removed based on quantified expression profiles and lowly expressed genes with a median Counts less than 10 were filtered out to reduce the influence of technical noise. A linear regression was fitted for each transcript with the log₂-transformed normalized values as outcome adjusted for age, sex, and processing factors, and used residual from the transcript as our final transcription dataset. The residuals represent a quantitative trait capturing variability in transcripts outcome not captured by known demographics or technical factors. Technical factors for DLPFC include batch, library size, percentage of aligned reads, percentage of coding bases, percentage of intergenic bases, percentage of ribosomal bases, percentage of UTR base, percentage of duplication, median 3 prime bias, median 5 prime to 3 prime bias, median CV coverage, pmi, and study index of ROS or MAP. Technical factors for AC and PCC are very similar. A detailed description of outlier removal, normalization, and calculation of the residuals in MSBB and Mayo are described elsewhere [93].

We assumed that differences in candidate gene expression would be associated with brain infarcts. A logistic regression was fitted for brain infarcts as the outcome and tested for the candidate gene expression while adjusting for age, sex, and processing factors. Details of neuropathological evaluation and qualifying determinants of infarcts in the ROSMAP dataset have been reported previously [75].

We performed association analyses of pathologically diagnosed AD with expression level of candidate gene across cells of the dorsolateral prefrontal cortex in 24 individuals from the ROSMAP cohort. A logistic regression was fitted for pathological AD as the outcome while adjusting for age, sex. A detailed description of the ROSMAP single nucleus RNA sequencing data are described elsewhere [3].

Causal mediation analysis

To quantify the involvement of gene expression in aging-related brain pathology in AD, we investigated whether the effect of gene expression on cerebrovascular pathology in AD brain would be mediated by AD specific pathology. We also investigated whether the effect of the AD pathology in brain infarcts would be mediated by candidate gene expression. We used a causal mediation analysis aimed at identifying whether the candidate expression resulted from amyloid or phosphorylated tau deposition or the reverse. In the mediation analysis, the mediated effect refers to an indirect effect of the exposure on outcome through a mediator. Direct effect refers to the effect of the exposure on the outcome after adjusting for the mediator. Total effect refers to the total effect of the exposure on the outcome, obtained by combining direct and indirect effects. Causal mediation modeling was performed using the R package mediation and confidence intervals were obtained by nonparametric bootstrap procedure with 1000 resamples [85]. In parallel, we performed cell type specific analyses of the expression of our gene of interest.

Human brain sections and immunohistochemistry

Human brain sections from BA9 prefrontal cortex were also obtained from the New York Brain Bank at Columbia University (Table S14) and immunohistochemical staining for FMNL2 and GFAP were performed as described [92] with the following modifications: heat-induced antigen retrieval was performed with pressure cooker, and concomitant biotin-based immunodetection was performed. Nine random images per patient from the sections were acquired with identical acquisition parameters to control brains and Arivis-based quantification was performed (script available upon request). The analyses were based on the overlapping surface area of GFAP and FMNL2 that is normalized to the total GFAP surface area. Automated masking was

quality controlled manually; images were excluded from the analyses if machine-predicted surfaces show substantial difference to manual selections. Analyses were performed in blind fashion: sample IDs were revealed after immunohistochemical stainings and quantifications for individual samples. Statistical comparisons were performed with Dunn's Kruskal–Wallis test and linear mixed effects model.

Mouse studies

Ethics statement and animal maintenance

All animal studies followed European animal regulations and were approved by the appropriate authority (Landesdirektion Sachsen, Germany) under license number TVV87/2016. To limit suffering and overall animal numbers, animals were treated with extraordinary caution. Mice were maintained on a 12-h alternating light and dark cycle, with free access to conventional mouse diet (chow) and water. Animals were housed in groups in normal ventilated cages, and after the surgeries, they were maintained in individual cages. Fixed gender mice aged between 52 and 54 weeks were used for analysis. Jackson Laboratories (Bar Harbor, ME, USA) provided the B6.Cg-Tg(APP695)3DboTG(PSEN1dE) mice, which were kept as a heterozygous breeding colony.

Stereotaxic injection for mouse brain injury

The brain tissue injury was induced by stereotaxic injection. The mouse was anesthetized with a combination of oxygen and isoflurane (49:1) (Baxter–HDG9623) flow during the procedure and put on a pre-warmed heat-pad to avoid hypothermia. Ear bars were used to keep the head immobile, and a protective ointment was applied to the eyes to prevent cornea dehydration. An analgesic was administered subcutaneously before to the surgery to reduce any potential pain afterward. The injury was caused in the right hemisphere, coordinates were ± 1.6 mm mediolateral, -1.9 mm anterior–posterior, and -1.9 mm dorsoventral from the Bregma, where the PBS was dispensed at 200 nL/min speed. The left hemisphere was used as a control for the analysis. The capillary was progressively retracted after the injection, followed by the ear being released. Mouse brain was analyzed 3 days after the injury via immunohistochemistry.

Tissue preparation

An overdose of Ketamine/Xylazine (0.25 mL per 25 g of body weight) was used to euthanize the mice, which were then transcardially perfused with NaCl (0.9 percent w/v) and 4% paraformaldehyde (PFA). Brains were extracted and post-fixed in 4% PFA overnight at 4 °C. Brains were placed in a

30% sucrose solution for 2–3 days to cryopreserve the fixed tissue. A sliding microtome (Leica SM2010) chilled with dry ice was used to cut coronal sections with a thickness of 40 μm . Free-floating sections were collected in six series and kept at $-20\text{ }^{\circ}\text{C}$ in cryoprotection solution (CPS; 25% ethylene glycol, 25% glycerol in 0.1 M phosphate buffer pH 7.4). For immunohistochemistry, every sixth section series of each brain was used.

Immunohistochemistry

Free-floating sections were rinsed three times in PBS before being blocked in a 10% Donkey Serum, 0.3% Tween 20, and $1\times$ PBS solution for 1 h at room temperature. Primary antibodies were diluted in PBS containing 3% donkey serum and 0.3% Tween-20 and sections were treated overnight at $4\text{ }^{\circ}\text{C}$. After 3 washes with PBS, secondary antibody conjugated with a chosen fluorophore was then incubated for four hours at room temperature. After a quick wash, samples are incubated for 15 min in 4,6-diamidino-2-phenylindole (DAPI) diluted in PBS. Additional washing steps were performed, and samples were mounted on glass slides.

Imaging

Fluorescence images were acquired using a spinning disc Zeiss Axio Observer.Z1 microscope (Oberkochen, Germany) equipped with ZEN software (version blue edition, v3.2, company, Carl Zeiss, Jena, Germany).

Zebrafish studies

Ethics statement

Animal experiments were carried out in accordance with the animal experimentation permits of Referate 24 (Veterinärwesen, Pharmazie, und GMP) of the state administration office of Saxony, Germany (Landesdirektion Sachsen), the ethical commission of TU Dresden (Kommission für Tierversuche), and the Institutional Animal Care and Use Committee (IACUC) at Columbia University (protocol number AC-AABN3554). Zebrafish handling and maintenance was according to the provided guidelines [1, 32, 51, 79] and EU Directive 2010/63 Article 33 and Annex III (permit numbers: TVV-35/2016, TVV-52/2015, TVV31/2019, and TVV39/2020). For zebrafish studies, 8–12 months old wild type AB strain, Tg(*her4.1*:GFP) [100] and Tg(*kdrl*:GFP) [40] reporter fish of both genders were used. In every experimental set, animals from the same fish clutch were randomly distributed for each experimental condition.

Amyloid- β 42 (A β 42) and morpholino injection

Cerebroventricular microinjection of Amyloid- β 42 peptides in adult zebrafish brain were performed as previously described [13]. Morpholinos were injected to embryos and adult zebrafish brains as described [11, 49]. For morpholino experiment, 10 μM concentration of control morpholinos, control morpholinos with A β 42 or *fnnl2a* + *fnnl2b* morpholinos with A β 42 were injected to adults. For embryos, 2 ng of morpholinos were injected. See Table S15 for more information on the reagents.

Histological preparation of zebrafish tissue and immunohistochemistry

Euthanasia and tissue preparation were performed as described [13]. 12- μm thick cryo-sections were prepared from these brain samples using a cryostat and collected onto glass slides which were then stored at $-20\text{ }^{\circ}\text{C}$. Immunohistochemistry was performed as described [13].

Imaging, quantifications, and statistical analyses

Images were acquired using ZEN software on a Zeiss fluorescent microscope with ApoTome or Zeiss Spinning Disc microscope. Images were analyzed using ZEN or Arivis Image processing software. For glial-vasculature interaction, automated quantification pipeline for at least 50% overlap between GFP (vasculature) and S100 β (glia) was developed in Arivis software (script available upon request). Quantifications were performed on z-stacks images obtained from the telencephalon sections (region between caudal olfactory bulb until the rostral optic tectum). 6–8 histological sections per animal were used for stereological analyses and quantifications. For colocalization in Fig. 2, ImageJ version 2.1.0/1.53c was used with default settings. A two-tailed Student's *t*-test was performed for comparison of two experimental groups, one-way ANOVA with Tukey's multiple comparison test were performed for comparison of multiple experimental groups. Statistical analyses were performed in GraphPad Prism software. Bars in the graphs indicate the mean values and 95% CI. *p* values less than 0.05 were considered significant. Significance is indicated by *($p < 0.05$), **($p < 0.01$), ***($p < 0.001$) or n.s. (not significant, $p > 0.05$). No sample set was excluded from the analyses unless the histological sections were damaged severely during the acquisition of the sections (constitutes less than 5% of all sections analyzed).

Results

Genetic analyses

Genome-wide array data were available from 10,287 non-Hispanic whites, 3404 Caribbean Hispanics and 978 African-Americans (Table 1). The majority of the participants were women (65%) and had a history of hypertension (70%).

A history of heart disease, hypertension and diabetes and measured BMI in the different cohorts were modestly correlated (spearman correlation coefficient ranging from 0.03 to 0.26, Supplementary Fig. 2. Principal component (PC) analysis was performed to create the CVRF score, summarizing the joint effect of the four risk factors for each cohort. The first principal component was used to represent the CVRF score, Supplementary Fig. 1 shows the contribution of each risk factor to the score. In all cohorts, diabetes and hypertension were highly correlated and most strongly influenced the CVRF score. The percentage of variance explained by principal component 1 for each ethnic group were: African-Americans 34.7%, non-Hispanics Whites 35.5%, Caribbean Hispanics 38.6%. Variance explained by the first four principal components and contributions of the risk factors to each component is also described in Table S1.

In a gene by CVRF interaction analysis of AD, three genes met the false discovery rate (FDR) adjusted p value of 0.05 using the adaptive gene-environment interaction (aGE) test (Table 2). One gene located on chromosome 2, Formin-like protein 2 (*FMNL2*), also met the Bonferroni corrected p value threshold for significance ($p = 6.6 \times 10^{-7}$). Cohort-level results showed nominal significance in all ethnic groups except in African-Americans. QQ plots for each cohort are shown in Supplementary Fig. 4. There was no evidence of inflation in any group. This *FMNL2* gene by CVRF score interaction was subsequently validated

using gene-environment set association test (GESAT) ($p = 7.7 \times 10^{-7}$). Other nominally significant genes are reported in Table S2. As an additional measure of *FMNL2* interaction with CVRF, we repeated the interaction test by constructing the CVRF as the sum of first two principal components. *FMNL2*-CVRF interaction was still robustly associated with AD ($p = 3.47 \times 10^{-4}$). Analyzing each risk factor of the CVRF separately, *FMNL2* interacts most strongly with history of hypertension ($p = 7.53 \times 10^{-4}$) and BMI (2.51×10^{-3}) (Table S3).

Meta-analysis of single nucleotide variants (SNP) within the *FMNL2* identified 130 nominally significant SNPs ($p < 0.05$) present in at least three cohorts and interacting with the CVRF score (Table S4). Two individual SNPs in *FMNL2* met the Bonferroni corrected p value in the interaction model rs57223657 ($p = 3.61 \times 10^{-4}$) and rs6760139 ($p = 3.63 \times 10^{-4}$). Random-effects model in meta-analysis was used as comparison and rs57223657 stayed similar ($p = 3.61 \times 10^{-4}$). Main genetic effect of rs57223657 was significant when adjusted for SNP-CVRF interaction effect and the CVRF score ($p = 0.004$).

FMNL2 expression in autopsy brains

We assumed that any gene or genes interacting with vascular risk factors to modify AD risk would be directly related to molecular pathways in AD and cerebrovascular disease. Using autopsied brain tissue from the ROSMAP with multi-region brain transcriptomes, higher expression of *FMNL2* was associated with pathological AD in all three regions sampled: the dorsolateral prefrontal cortex ($p = 0.004$), the posterior cingulate cortex ($p = 0.001$) and in the anterior caudate ($p = 0.012$). In the ROSMAP cohort a small number of participants were considered cognitively normal but had autopsy findings confirming hallmarks of AD in brain. As a sensitivity analysis, we tested the association of

Table 2 Gene-CVRF score interaction results in GWAS: Top ten genes interacted with the CVRF score to modify AD risk, sorted by meta-analysis p value

Gene	Chr	P_{ROSMAP}	$P_{\text{WHICAP AA}}$	$P_{\text{WHICAP Whites}}$	P_{CH}	P_{NACC}	P_{Meta}	P_{FDR}
<i>FMNL2</i>	2	0.001	0.189	0.038	0.009	0.012	6.59×10^{-7}	0.012
<i>LOC401357</i>	7	0.172	0.362	0.020	0.001	0.006	1.13×10^{-6}	0.012
<i>AMMECRIL</i>	2	0.940	0.073	0.044	0.005	0.001	2.43×10^{-6}	0.017
<i>CFAP99</i>	4	0.549	0.937	0.424	4.1×10^{-4}	0.002	1.27×10^{-5}	0.068
<i>SLC22A14</i>	3	0.294	0.425	0.307	0.293	4.90×10^{-5}	1.81×10^{-5}	0.070
<i>PRG3</i>	11	0.387	0.090	0.012	0.205	0.001	1.96×10^{-5}	0.070
<i>PTPRF</i>	1	0.056	0.563	0.532	0.659	3.10×10^{-5}	2.84×10^{-5}	0.087
<i>PLA2G4E</i>	15	0.254	0.893	0.219	0.509	3.20×10^{-5}	4.55×10^{-5}	0.095
<i>ACACB</i>	12	NA	0.184	0.135	0.038	0.004	4.98×10^{-5}	0.095
<i>LINC00353</i>	13	0.004	0.270	0.267	0.106	0.014	5.29×10^{-5}	0.095

P_{cohort} p value of the gene-CVRF score interaction test in each cohort, AA African-Americans, CH WHI-CAP and EFIGA Caribbean Hispanics, P_{Meta} p value of the meta-analyzed gene-CVRF score interaction results from five cohorts, P_{FDR} FDR adjusted p value of the meta-analysis p value, NA not available

FMNL2 expression by restricting the analysis to individuals with both clinical and pathological AD compared them with healthy individuals without ante and post-mortem AD. The *FMNL2* association with AD was even stronger ($p=7.89E-08$; Table S5). Available data from the Mount Sinai Brain Bank, also showed increase *FMNL2* expression in the parahippocampal gyrus ($p=0.0004$) in pathological AD, and in data from the Mayo Clinical Brain Bank, *FMNL2* expression was increased in the temporal cortex ($p=0.011$) in pathological AD (Table 3).

Using data from ROSMAP, we found that an increased expression of *FMNL2* in AD brain was associated with A β (adjusted $\beta=0.188$, $p=0.034$) and tau deposition (adjusted $\beta=0.415$, $p=0.011$). The expression level of *FMNL2* was also significantly higher in those with gross chronic infarcts in cortex compared to those without infarctions (adjusted for age, sex, and processing factors $\beta=1.024$, $p_{FDR}=0.003$;

Fig. 1a; Table 4). Restricted to pathological AD, *FMNL2* expression was higher in those with, compared to those without, gross chronic infarcts in cortex (adjusted $\beta=0.792$, $p=0.025$). A mediation model suggested that *FMNL2* expression mediates the association of Amyloid- β and phosphorylated tau deposition with brain infarcts, although no direct association was observed between them. The mediation analysis suggested an indirect effect, in which A β or tau deposition increased *FMNL2* expression, which was then associated with brain infarcts (mediation effect: $p=0.002$ amyloid; $p < 2 \times 10^{-16}$ tau; Table S6). Of interest, the ante-mortem CVRF score was also modestly increased in those with gross chronic infarcts (detected post-mortem) compared to no infarcts ($\beta=0.21$, $p=0.036$).

Rs77136812 in *FMNL2* was among 14 SNPs that were correlated with *FMNL2* expression ($\beta=0.118$, $p=0.027$) (Table S7). In addition, SNP rs4664586 was associated

Table 3 Association of *FMNL2* expression with pathologic diagnosis of AD using the multi-region brain transcriptomes from three cohorts

Cohort	Brain region	<i>n</i>	<i>b</i>	SE	<i>p</i>
ROSMAP	Dorsolateral prefrontal cortex (DLPFC)	1092	0.582	0.200	0.004
	Posterior cingulate cortex (PCC)	661	1.040	0.316	0.001
	Anterior caudate (AC)	731	0.875	0.350	0.012
MSBB	Frontal pole (MB10)	214	0.369	0.623	0.554
	Superior temporal gyrus (BM22)	191	1.038	0.718	0.149
	Parahippocampal gyrus (BM36)	161	2.970	0.833	0.0004
	Inferior frontal gyrus (BM44)	186	1.235	0.652	0.058
Mayo	Temporal cortex (TCX)	261	1.204	0.473	0.011
	Cerebellum (CBE)	262	-0.348	0.642	0.588

n sample size, *b* estimate, *SE* standard error, *p* *p* value




Fig. 1 *FMNL2* expression level by brain infarcts. **a** Distribution of expression level of *FMNL2* in those with gross chronic infarction in cortex compared to those without infarction was statistically significant (adjusted for age, sex, and processing factors $b=1.024$, $p_{FDR}=0.003$). **b** Distribution of *FMNL2* expression in those with pathological AD and gross chronic infarction in cortex compared to those with pathological AD and no infarction, in the dorsolateral prefrontal cortex from ROSMAP was statistically significant (adjusted $b=0.792$, $p=0.025$). A logistic regression was fitted for the brain

infarcts as outcome and *FMNL2* expression level (log₂-transformed normalized transcripts per million values) as exposure adjusted for age, sex, and processing factors. For visualization purposes, the residual of *FMNL2* expression level (y-axis) was used to represent the residual of transcripts from fitting the linear regression on the *FMNL2* expression level adjusted for age, sex, and processing factors, capturing variability in transcripts outcome not captured by known demographics or processing factors

Table 4 Association of expression level of *FMNL2* with brain infarcts in all brain samples in the dorsolateral prefrontal cortex from ROSMAP

Infarcts	<i>b</i>	SE	<i>p</i>	<i>P</i> _{FDR}
Gross chronic infarctions in cortex	1.024	0.295	5.21×10^{-4}	0.003
Gross subacute infarctions in cortex	0.697	0.467	0.135	0.181
Micro subacute infarctions in cortex	0.017	0.542	0.975	0.975
Chronic infarctions in cortex, regardless of size	0.525	0.226	0.020	0.060
Subacute infarctions in cortex, regardless of size	0.519	0.361	0.151	0.181
Infarctions in cortex, regardless of size/age	0.388	0.206	0.060	0.120

b estimate, *SE* standard error, *p* *p* value, *P*_{FDR} FDR adjusted *p* value. The expression of *FMNL2* was increased in pathological AD with gross chronic infarcts compared to pathological AD without gross chronic infarcts (*b*=0.792, *p*=0.025)

with hypomethylation of several CPG sites surrounding the *FMNL2* gene, the strongest having a *p* value of 6.75×10^{-7} , indicated that one of these variants might also have regulatory effects on expression (Table S8).

We then tested the cell-specific expression of *FMNL2* using data from single nucleus RNA-sequencing of the frontal cortex in 24 individuals from the ROSMAP cohort. *FMNL2* was highly expressed (*p*=0.024) in a subset of astrocytes enriched in interferon response genes, derived from AD brains compared to brain tissue from non-demented individuals.

Zebrafish model

To determine the putative evolution of *FMNL2* expression changes in pathological AD, we used a previously described in vivo zebrafish model of amyloidosis [11–13, 24]. The zebrafish model of amyloid β pathology is an acute model where injection of amyloid peptides leads to an intracellular aggregation/polymerization of amyloid peptides (Supplementary Fig. 5), which lead to phenotypes reminiscent of the alterations in mammalian systems (e.g., cell death, synaptic degeneration, inflammation, glial hypertrophy and cognitive impairment) [12–14]. This model allows to mechanistically investigate the effects of amyloidosis in a vertebrate brain within a short time, and the molecular understanding from zebrafish model is relevant to mammalian models and human AD [48, 50, 66, 69, 77].


Based on our existing zebrafish single cell sequencing data, we determined that *fmln2a*, a zebrafish ortholog of human *FMNL2*, is expressed in *her4.1*-positive glial cells (Fig. 2a). To confirm this, we analyzed the bulk RNA-seq data from sorted *her4.1*-positive glial in transgenic reporter line Tg(*her4.1*:GFP), which marked the astroglial cells in adult zebrafish in control and amyloid- β 42-injected brains. We found that amyloid deposition significantly increased the expression of *fmln2a* in astroglia (Fig. 2a). *Fmnl2* is localized to the cell bodies and the projections of the astroglia in the healthy adult zebrafish brain as determined by immunohistochemistry with an antibody cross-reactive

to *FMNL2* protein (Fig. 2c, c'). Amyloid β increased the *FMNL2* reactivity levels in the astroglia consistent with the gliotic hypertrophy (Fig. 2d, d'). *FMNL2* and *her.1*-driven GFP expression strongly correlates, indicating that these proteins co-localize in astroglial cells (Fig. 2g, h). We found that the other ortholog of human *FMNL2* gene in zebrafish, *fmln2b*, is primarily expressed in neuronal populations as determined by single cell sequencing (Supplementary Fig. 6a). We determined the specificity of the *FMNL2* antibody in zebrafish by performing the antibody staining only with the secondary antibody, which resulted in no signal in glial extensions and punctate staining in the parenchyma (Supplementary Fig. 6b), indicating that *Fmnl2* immunohistochemistry in zebrafish is detecting true signals. Neuronal and glial *Fmnl2* immunoreactivity can be distinguished in neurons and glia by the signal in the radial extensions (glial *Fmnl2*) and parenchymal perinuclear staining (neuronal *Fmnl2*) (Supplementary Fig. 6c).

The radially elongated endfeet of astroglia (S100 β) in zebrafish telencephalon coalesce at ventrolateral blood vessels (ZO-1) (Fig. 3a–a''), which displayed colocalized astroglial endfeet and tight junctions of the blood vessels (Fig. 3b, b'). This interaction was verified using a transgenic zebrafish reporter line Tg(*kdrl*:GFP), which marked the endothelial cells of the blood vessels and S100 β immunolabeling that marked the astrocytic endfeet (Fig. 3c, c'). To determine if these gliovascular interactions are affected in amyloid pathology, we performed immunohistochemical staining in amyloid β -injected animals and found that gliovascular interactions were less pronounced compared to the control (Fig. 3d, d'). To determine this change in a quantitative manner, we developed an automated image analyses pipeline that determines the colocalization of glial endfeet and blood vessels (Fig. 3e) and found that the surface area of gliovascular interactions reduced significantly upon amyloid β (Fig. 3f; Table S9). This result suggest that astroglial-vascular contacts undergo a relaxation upon amyloid β toxicity.

To determine the role of *Fmnl2* in the dynamic regulation of gliovascular interactions and amyloid deposition, we knocked down *Fmnl2* activity by cerebroventricular

Fig. 2 Expression of *fmm12a* in zebrafish brain overlaps with astroglia. **a** Single cell sequencing tSNE plots for *her4.1* and *fmm12a* in adult zebrafish telencephalon. **b** Amyloid toxicity assay and bulk RNA sequencing results for *fmm12a* gene expression. **c, d** Double immunohistochemical staining (dIHCS) for *her4.1*: GFP (astroglia) and Fmm12 in control (**c**) and amyloid-injected (**d**) brains with DAPI counterstain. **c', d'** Individual fluorescent channels for Fmm12. **e, f** Higher magnification image showing overlapping Fmm12 and *her4.1*-driven GFP. **g, h** Double channel colocalization analyses of **e** and **f**. R Pearson correlation coefficient, ρ Spearman's rank coefficient. Scale bars as indicated






Fig. 3 *Fmnl2* is required for remodeling of gliovascular interactions. **a** diHCs for S100 β (astroglia) and ZO-1 (tight junctions/vessels) with DAPI counterstain. **a'**, **a''** Individual channels for the inset in **a**. **b** Higher magnification view of dorsoventral gliovascular (GV) junctions. **b'** Close-up of inset in **b**. Arrows indicate overlaps. **c**, **d** diHCs for *kdr1:GFP* (blood vessels) and S100 β in control (**c**) and amyloid-injected (**d**) brains with DAPI counterstain. **c'**, **d'** DAPI omitted from **c** and **d**. **e** Representative snapshot of the automated quantification

of the surface of gliovascular interactions. **f** Quantification results of GV interactions. **g**, **h** diHCs for *kdr1:GFP* and S100 β in amyloid injected brains that were co-injected with control morpholino (**g**) and *fmln2a/b* morpholino (**h**) with DAPI counterstain. **g'**, **h'** DAPI omitted from **g** and **h**. **i** Close-up image of blood vessels interacting with glial endfeet. **j** Quantification results of GV interactions. Yellow arrows in **c'**, **d'**, **g'** and **h'** indicate exemplary gliovascular interactions. Scale bars as indicated

microinjection of *fmln2*-targeting morpholinos, which were previously verified in zebrafish [91] and we also determined to be effective for reducing *Fmnl2* expression in zebrafish (Supplementary Fig. 6d). Cerebroventricular microinjection targets mainly the ventricular cells and therefore would effectively knock-down *Fmnl2* in astroglia. We found that relaxation of gliovascular interactions upon amyloid toxicity was negatively affected by *fmln2* knock-down in zebrafish brains (Fig. 3g–j; Table S10), which suggested that gliovascular remodeling in response to amyloid toxicity requires *Fmnl2* function.

Defects in blood–brain barrier integrity are associated with several chronic diseases. An increase in blood–brain barrier permeability, required for the passage of toxic aggregates from brain to blood as well as for immune cells to infiltrate the brain to attack the toxic entities at earlier stages of disease progression [25], suggests that stage-specific regulation of gliovascular interactions modulates the cerebrovascular pathology in AD. To determine whether the microglial interactions with the blood vessels are affected by *Fmnl2* function, we performed immunohistochemical

staining for L-plastin (microglial marker) in relation to the blood vessels (Fig. 4a–f). We found that while amyloid β injection increased the microglia-vasculature contact compared to control animals, and *fmln2* knock-down reduced the extent of this contact and the number of activated microglia (Fig. 4g; Table S11). These results suggest that the remodeling of the gliovascular interactions by *fmln2* may be a critical factor for microglial dynamics or leukocyte extravasation from the blood vessels.

Microglial activity and vascular dynamics are important for clearance mechanisms in the brain. If *Fmnl2* knock-down resulted in reduced number of activated microglia, it may have an impact on amyloid clearance as well. Therefore, we analyzed whether *Fmnl2* knock-down could alter the clearance and vascular deposition of amyloid β . After acute amyloidosis through microinjection of amyloid, we performed immunostaining for amyloid β , and analyzed the extent of amyloid aggregation near the blood vessels with and without *fmln2* knock-down (Fig. 4h). We observed that *fmln2* knock-down zebrafish brains showed higher levels of amyloid aggregation around the blood vessels compared to




Fig. 4 *Fmnl2* knock-down reduces the number of activated microglia and alters the amyloid load. **a–f** diHCs for L-plastin (microglia) and *kdrl:GFP* with DAPI counterstain on control morpholino (**a, b**), Aβ42+ control morpholino (**c, d**), and Aβ42+ *fmdl2a/b* morpholino (**e, f**) injected brains. **a', b', c'** L-plastin channel alone. **g** Quantifi-

cation graph for the number of activated microglia in the indicated conditions. **h** High magnification images from three blood vessels in Aβ42+ control morpholino-injected zebrafish brains (left column) and Aβ42+ *fmdl2a/b* morpholino-injected brains (right column). Scale bars as indicated

control animals, which could be due to impaired amyloid clearance because of reduced number of activated microglia (Fig. 4h). These findings suggest that relaxed gliovascular interactions through the activity of *Fmnl2* is required for amyloid clearance through bloodstream and/or interaction of the immune cells with the vasculature, but not for blood vessel development (Supplementary Fig. 6d–f; Tables S9 and S12).

Mouse model of AD recapitulates gliovascular remodeling and upregulation of *Fmnl2*

To determine whether chronic amyloid pathology in mammalian models of AD would alter *Fmnl2* expression and gliovascular remodeling, we utilized a well-established AD model APP/PS1dE9 [39] (Fig. 5). Compared to age-matched control mice (12 months old) (Fig. 5a–d), APP/PS1dE9 mice shows extensive amyloid plaques (Fig. 5e, f), gliosis (Fig. 5g) and elevated levels of *Fmnl2* (Fig. 5h), supporting our previous findings. To determine whether gliovascular interactions are also altered in mice upon AD pathology, we performed triple immunostaining for Gfap (astroglia), *Fmnl2* and Cd31 (blood vessels) (Fig. 5i–p). We observed that concomitant to elevated levels of *Fmnl2* and gliosis, astroglial interactions with the blood vessels are reduced with pathology (Fig. 5i, m). *Fmnl2* staining was quality controlled by excluding the primary antibody, which confirmed that the signal for *Fmnl2* is specific (Supplementary Fig. 7). These results indicate that in acute or chronic amyloid pathology models in zebrafish and mouse, upregulation of *Fmnl2* and reduction in gliovascular interactions are consistent.

AD pathology is strongly associated with a gliotic response in astroglia, and the gliovascular remodeling response could be a generic outcome due to gliosis. To test whether *Fmnl2* upregulation and relaxation of the gliovascular interactions are dependent on gliosis, we performed traumatic injury in the cerebral cortex of healthy mouse brains (Supplementary Fig. 8). Compared to control mice, injured brains showed extensive gliotic response; yet the gliovascular interactions and the levels of *Fmnl2* were not significantly altered (Supplementary Fig. 8). These results suggest that the remodeling of gliovascular interactions and concomitant upregulation of *Fmnl2* could be a specific response to amyloid pathology.

Validation in post-mortem human brains

Functional studies imply that vascular risk factors would increase the expression of *FMNL2* in humans with AD. To test this hypothesis, we performed immunohistochemical staining in post-mortem human brains for *FMNL2* and GFAP (Fig. 6) (control, AD, Primary age-related Tauopathy [PART] with or without cardiovascular pathology, Tables S12 and S13). We observed that in control brains, *FMNL2* expression was punctate and scarce around the blood vessels (Fig. 6a, b), while in early onset AD and in AD with severe atherosclerosis, there was significant *FMNL2* expression that delineated the blood vessels (Fig. 6c–f). In these brains, astroglia were reactive and in some regions glial endfeet were detached from the vessel. In patients with primary age-related tauopathy, *FMNL2* localizes around the blood vessels albeit less prominent




Fig. 5 Upregulated *Fmnl2* and altered gliovascular interactions observed in chronic APP/PS1dE9 AD model in mice. **a, h** Triple immunohistochemical stainings (tIHC) for Gfap (astroglia), 4G8 (amyloid plaques) and *Fmnl2* with DAPI counterstain in control (**a, d**) and APP/PS1dE9 mice (**e–h**) at 12 months of age. Panels are from cerebral cortex. Black-white panels are individual fluorescence chan-


nels of the composite images in **a** and **e**. **i–p** tIHC for Gfap, Cd31 (blood vessel) and *Fmnl2* with DAPI counterstain in control (**i–l**) and APP/PS1dE9 mice (**m–p**) at 12 months of age. Panels are from cerebral cortex. Black-white panels are individual fluorescence channels of the composite images in **i** and **m**. Scale bars as indicated

than in AD (Fig. 6g, h). The tight associations of astroglia to the blood vessels inversely correlate with FMNL2 expression (Fig. 6i). Quantification of FMNL2 expression in control and patients showed a significant increase in FMNL2 in astroglial cells in disease conditions (Fig. 6j), supporting the findings that FMNL2 is a response to AD and is involved in regulating the gliovascular interactions.

Discussion

A major effort to identify genes and loci associated with AD risk has been underway for several decades [41, 54]. Many of these genes have been replicated and confirmed in other studies [15, 53]. The focus has now shifted to fully

understand mechanisms by which variants in genes lead to disease. Epidemiological and neuropathological research has established an intertwined relationship between AD and cerebrovascular disease and its antecedents. Yet, our understanding of the course of this inter-dependent relationship is unclear. To probe the interaction between CVRFs, cerebrovascular disease and AD based on the genotype–phenotype relationship, we used data from five cohorts of different ancestries to perform an unbiased genome-wide association study of the interaction effects of CVRFs and AD genetic variants. We found that *FMNL2*, formin-like protein 2, significantly interacted with the CVRF score to modify AD risk. We also found that the association between the CVRF scores and AD differed by SNP genotypes within *FMNL2*. *FMNL2* brain expression was increased in pathological AD,



with A β and tau deposition and with brain infarcts independently. The mediation analysis allowed us to hypothesize that the effects of FMNL2 expression on pathological AD were related to accumulation of A β and tau deposition.

Furthermore, we found that FMNL2 to be highly expressed in astrocytes, a key cell type of interest in AD. SNPs in *FMNL2* interacting with *CVRF* are also correlated with gene expression and hypo-methylation levels suggesting

Fig. 6 FMNL2 expression is upregulated at gliovascular junctions in AD patients. **a–h** dIHC for FMNL2 and GFAP in control (**a, b**), early onset AD patient (**c, d**), AD patient with severe atherosclerosis (**e, f**), and primary age-related Tauopathy (PART) with mild atherosclerosis patient (**g, h**). Black and white images are individual fluorescent channels of the leftmost panels for FMNL2 and GFAP. Rightmost panels (**b, d, f, h**) are higher-magnification composite images around a representative blood vessel. **i** Two examples of astroglia (GFAP+, green) contacting blood vessels (bv), and their expression of FMNL2 (violet). Arrows indicate contact with blood vessels. In AD, astroglia express FMNL2 and its endfeet is retracted from the blood vessel, while in controls tight association is observed. Black-white panels indicate individual fluorescence channels. **j** Arivis-based automated image quantification pipeline and the quantification graph for FMNL2 expression in human brains. Comparisons are for every diseased brain to control. with Dunn's Kruskal–Wallis test. Scale bars as indicated

a regulatory effect of common polymorphisms leading to increased FMNL2 expression.

A strength of the current study is the inclusion of three ethnic groups, which is particularly important in the study of genetics and cerebrovascular disease, for two reasons. First, specific variants associated with disease within a gene can differ between ethnic groups based on linkage disequilibrium (LD) structure. Identifying significant SNPs through a meta-analysis across cohorts and collapsing SNPs within gene for gene-based analyses increases the power of discovery and generalizability of the results. Second, there are differences in the frequency of cerebrovascular disease and associated CVRFs between non-Hispanic Whites, African-Americans, and Caribbean Hispanics. Clinically, these results could have important implications for personalized treatment plans, suggesting more aggressive treatments of cardiovascular and cerebrovascular risk factors in persons with specified genotypes. Third, we bring together data from three species—human, mouse, and zebrafish—and demonstrate a validation-oriented functional genomics pipeline to analyze the biological mechanisms of action for increasing number of AD-related genes [6] and their evolutionary conservation. Finally, we also propose zebrafish as a useful experimental model for amyloid β pathology, an important aspect of AD.

Previous studies of gene-environment interactions in AD have focused on candidate genes, stemming from prior genome-wide studies of AD or cerebrovascular disease (e.g., [19, 95]). Here we focused on a genome-wide, unbiased interaction approach to identify novel genes that interact with CVRFs in AD. Hypertension [29, 87], type II diabetes [89] and obesity [5] have each been associated with AD, cerebrovascular disease and alterations in the blood–brain-barrier integrity. The resulting microvascular dysfunction increases the permeability of the blood–brain barrier, oxidative stress, activation of immune mechanisms and leakage of proteins. Additionally, vascular defects generate hypoxic conditions that enhance the toxic protein aggregation [73,

80]. Therefore, these changes increase the demand for waste removal mechanisms in the brain.

How do variants in FMNL2 contribute to the cerebrovascular pathology in AD?

FMNL2 encodes a formin-related protein. Formins are important in regulating actin and microtubules, with cellular effects and consequences in cell morphology, cytoskeletal organization and cell–cell contact [30] and are implicated in AD pathology [35, 68]. Based on our results here, we propose that *FMNL2* regulates cell–cell interactions between glia and vasculature, and the clearance of extracellular aggregates. Astroglial endfeet form a perivascular space that is involved in arterial pulsation-dependent clearance [10]. The size of the astroglia-regulated interstitial space correlates with the drainage efficiency of the brain, for instance sleep-dependent adrenergic signaling expands the glymphatic space [76, 98]. However, with a higher load of extracellular protein aggregation, more efficient mechanisms such as the clearance through blood–brain barrier [84], where major amyloid-binding efflux receptor complexes including CLU, LRP1/2 and VLDLR are present [97], is required. *FMNL2*-mediated gliovascular remodeling could be a mechanism to potentiate the clearance through blood–brain barrier. Notwithstanding the elevated protein aggregation, clearance mechanisms become less efficient with aging and the efflux receptor expression increases [67]. *FMNL2*-mediated enlargement of perivascular space can serve to facilitate both glymphatic and blood–brain barrier clearance mechanisms. Recent findings confirm our hypothesis that perivascular remodeling is a critical response to amyloid pathology [21, 46] and could act as the interface between CVRFs and AD. A recent single cell transcriptomics analyses also confirmed our findings that FMNL2 is upregulated in astroglial cell populations in human AD brains [37]. Additionally, detached gliovascular interactions can lead to immune cell infiltration to the brain from the blood and may help the initial attempts of amyloid clearance [18, 36], which is supported by our findings that *fmln2* knock-down reduces the microglia that contact the blood vessels in zebrafish.

The long-term consequence of gliovascular detachment is unclear [47, 82], as breached blood–brain-barrier could inadvertently lead to exacerbation of the disease pathology. Additionally, whether the gliovascular endfeet retraction is a consequence of a generic gliotic response or is part of a disease-associated mechanism is debated. Our results showed that amyloid aggregation but not the traumatic injury induced FMNL2 expression, suggesting that FMNL2-regulated astroglial endfeet remodeling could be preferentially related to AD pathophysiology. A recent study demonstrating that selective focal ablation of astroglia endfeet around the blood vessels does not cause blood–brain-barrier

disruption and gliovascular contacts are efficiently replaced [62] supports our findings.

In this study, we experimentally showed that (1) *FMNL2* is expressed in astroglial cells, (2) *FMNL2* is upregulated with amyloid deposition in zebrafish, mouse, and human brains, (3) gliovascular interactions loosen with the disease pathology in three species, (4) this response requires *FMNL2*, and (5) loss of *FMNL2* function leads to amyloid deposition and reduced immune response. Post-mortem human brain immunohistochemical staining also confirmed that compared to control individuals, patients with AD have a significant increase in the expression of *FMNL2* near the glial endfeet at the blood vessels and in astrocytes that appear hypertrophic and reactive. We also observed that glial end feet were arrayed around the blood vessels in controls while this arrayed structure is impaired and show a dilated appearance concomitant to prominent *FMNL2* expression. Based on these results, we propose that *FMNL2* functions in astroglial cells to regulate the extent of gliovascular interactions and toxic protein clearance from the brain on demand. The role of *FMNL2* may also be required in other proteinopathies such as progressive age-related tauopathy, and *FMNL2* is also upregulated and delineated in blood vessel structures.

Gliovascular contacts are important components of the blood–brain barrier, and they partake in sustained homeostasis and clearance of amyloid β [99, 102]. The role of *FMNL2* in amyloid clearance is supported by the findings where the knock-down of *FMNL2* protein resulted in the defective sorting into late endosomes and lysosomes [43]. Abnormalities in the endosomal-lysosomal network are known to be important to the mechanism of neurodegeneration and AD [63]. We do not exclude that *FMNL2* could function in other cell types such as pericytes around the blood vessels to regulate the clearance and drainage mechanisms as well as to control the immune response either by altering microglia–blood vessel interactions or extravasation of immune cells into the brain. Future studies aiming at elucidating disease stage and cell-specific roles of *FMNL2* will be instrumental to further delineate the role of this protein and to propose new drug candidates.

The animal models that we used in this study—zebrafish and mouse—reflect the acute and chronic pathological changes and cellular response to amyloidosis. We recognize that the complex late-stage cognitive decline in AD may not be fully represented in these model systems. However, the post-mortem human tissue analyses, AD cohort studies and single cell datasets are relevant to the cognitive decline in AD through clinical (e.g., cognitive assessment scores) and neuropathological (e.g., Braak staging and histological analyses) aspects. Our hypothesis favors for an *FMNL2*-related pathological mechanism that is likely to initiate during the early course of the disease and extend toward

the later stages. In all our investigations, the dynamics of *FMNL2* was consistent either in acute zebrafish model, chronic mouse model or post-mortem human brains with documented clinical and pathological AD. This suggests that the biological role of *FMNL2* and the cellular interactions between neuro-glio-vascular niche cells could be an early response to the disease and extends toward later stages even when cognitive decline manifests. The relationship of clearance to the cognitive decline and brain atrophy is yet to be investigated.

FMNL2 is most highly expressed in the brain. In a study of ischemic stroke in young individuals ($n = 1816$), one SNP was found to be associated ($rs2304556$ $p = 1.18 \times 10^{-7}$) [23]. Interestingly, we found that increased *FMNL2* expression (*ENSG00000157827*) was associated with brain infarcts and AD independently, suggesting that this gene may be involved in a shared molecular mechanism with cerebrovascular disease. The SNP with the highest significant association in our study, $rs57223657$, is a point mutation in the third intron of *FMNL2* gene, where a promoter regulatory flank region resides. Intronic regions that contain gene regulatory, or enhancer functions are known to be critical determinants of gene expression and function [71, 72]. Thus, it is possible that regulatory variants of *FMNL2* may also alter gene function and the extent of the AD pathology at least through the regulation of gliovascular interactions. The multidisciplinary work reported here demonstrates the unique involvement of genes, *FMNL2*, and antecedent CVRFs in AD with human GWAS and in vivo animal model data.

While this study has several strengths, we recognize that there are also some limitations. First, we relied on self-report of three of the four vascular risk factors. While this approach is reliable and valid [45] it is also possible some individuals responded incorrectly. However, we did measure the fourth, BMI, directly. Second, we did not consider the possible effects of medications used to treat vascular risk factors, such as hypertension or diabetes. We were unable to define more deeply some of the cardiovascular diseases. In some groups, investigators only reported “any heart disease”, while others included information on the specific heart condition. We used a transient knock-down of *FMNL2* function in an acute amyloidosis zebrafish model, and a model of chronic amyloid pathology in mouse. A gene editing approach coupled to chronic models to mimic human *FMNL2* SNP variants will help to capture long-term effects of *FMNL2* on vascular risk factors and AD pathology in the zebrafish or mouse experimental models.

Taken together, this investigation implies that hypertension, diabetes, heart disease and obesity are more likely to have acquired cerebrovascular disease in the brain and are at higher risk for AD. In these patients, *FMNL2* expression resulting from the vascular risk factors and the resulting cerebrovascular pathology regulate the ongoing deposition of

amyloid and tau proteins by altering the normal interplay between glia and the vasculature and ultimately the clearance of extracellular aggregates (Supplementary Fig. 9). Our results also indicate that *FMNL2* expression is upregulated in the presence of CVRFs among individuals who develop AD, and that having both conditions augment the effect of *FMNL2* on AD pathology. The sequence of events—whether CVRF or AD comes first—will be better addressed with longitudinal experimental models for both diseases, yet our mediation analyses and functional experiments suggest that CVRF potentiates the AD pathology. Expanding on the relationship of genes and loci identified here, along with expanded basic molecular work will move us closer to conceptualizing the etiological interaction between AD and cerebrovascular disease and hopefully identifying therapeutic targets for AD.

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1007/s00401-022-02431-6>.

Acknowledgements This research is supported by National Institutes of Health grants RF1AG054023 (R.M.), R01 AG067501 (R.M.), RF1AG066107 (R.M.), R01AG072474 (R.M.), P30AG10161 (D.A.B.), R01AG15819 (D.A.B.), R01AG17917 (D.A.B.), U01AG61356 (D.A.B.), R01AG036836 (P.L.D.), U01AG046152 (P.L.D. and D.A.B.), Taub Institute Schaefer Research Scholars Award (C.K.), German Center for Neurodegenerative Diseases (C.K.) and TAME-AD (The Thompson Family Foundation Program for Accelerated Medicine Exploration in Alzheimer's Disease and Related Disorders of the Nervous System).

Author contributions BNV and RM conceived the study. DRD, RAL, MM, DR, IZJ, WAK, AMB, JJM. RM were instrumental in the collection of data from the various cohorts and provided phenotypic information. AJL, NSR, GT, SS, and BNV performed genetic analyses. JAS, DAB, PLD provided the autopsy data. VM performed single cell work. XEF selected the post-mortem human brains and prepared sections for analyses. PB, SALC, TS, CK performed the experiments and statistical analyses in the zebrafish and mouse model. CK, TS, PB performed the immunohistochemical stainings, quantifications and analyses of the post-mortem human brains. CK and RM provided interpretation of the zebrafish study and post-mortem human brains. AJL, NSR, CK, BNV, RM contributed to the interpretation of the results. AJL, NSR, CK, BNV, and RM wrote the manuscript. All authors contributed to data acquisition and provided critical feedback on the manuscript.

Data availability Genetic data for all cohorts is available at the National Institute on Aging Genetics of Alzheimer's Disease Data Storage Site (NIAGADS; <https://www.niagads.org>). Primary clinical data for WHI-CAP and EFIGA data are available at <https://www.neurology.columbia.edu/research/research-programs-and-partners/alzheimers-disease-research-center-adrc/investigators/investigator-resources>. Clinical data from NACC data is accessible on request at <https://naccdata.org>. Clinical data from ROSMAP data is accessible on request at <https://www.radc.rush.edu>. For the RNA sequencing data, gene-level transcript values in counts and normalized expression data from ROSMAP are available on the AMP-AD Knowledge Portal at Synapse (<https://adknowledgeportal.synapse.org>) (Synapse: syn25741873). The residual expressions from gene transcripts are available at Synapse (ROSMAP: syn25741873, MSBB: syn8485027, and Mayo: syn8466826). The ROSMAP single nucleus RNA sequencing data and the description of the data are available at Synapse (Synapse ID: syn16780177). Expression datasets for

zebrafish are publicly available as NCBI GEO accessions GSE74326 and GSE161834.

Code availability We used publicly available statistical software to perform analyses in the Methods section. Code to perform analyses in this manuscript are available from the author upon request (A.J.L.).

Declarations

Conflict of interest C.K. has executive function in Neuron-D GmbH (Germany), which had no financial relationship to or influence on this study.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

1. Alestrom P, D'Angelo L, Midtlyng PJ, Schorderet DF, Schulte-Merker S, Sohm F et al (2019) Zebrafish: housing and husbandry recommendations. *Lab Anim*. <https://doi.org/10.1177/0023677219869037>
2. Allen M, Carrasquillo MM, Funk C, Heavner BD, Zou F, Younkin CS et al (2016) Human whole genome genotype and transcriptome data for Alzheimer's and other neurodegenerative diseases. *Sci Data* 3:160089. <https://doi.org/10.1038/sdata.2016.89>
3. Anael Cain MT, McCabe C, Hekselman I, White CC, Green G, Rozenblatt-Rosen O et al (2020) Multi-cellular communities are perturbed in the aging human brain and with Alzheimer's disease. *bioRxiv*. <https://doi.org/10.1101/2020.12.22.424084>
4. Attems J, Jellinger KA (2014) The overlap between vascular disease and Alzheimer's disease—lessons from pathology. *BMC Med* 12:206. <https://doi.org/10.1186/s12916-014-0206-2>
5. Balasubramanian P, Kiss T, Tarantini S, Nyul-Toth A, Ahire C, Yabluchanskiy A et al (2021) Obesity-induced cognitive impairment in older adults: a microvascular perspective. *Am J Physiol Heart Circ Physiol* 320:H740–H761. <https://doi.org/10.1152/ajpheart.00736.2020>
6. Bellenguez C, Kucukali F, Jansen IE, Kleindam L, Moreno-Grau S, Amin N et al (2022) New insights into the genetic etiology of Alzheimer's disease and related dementias. *Nat Genet*. <https://doi.org/10.1038/s41588-022-01024-z>
7. Bennett DA, Buchman AS, Boyle PA, Barnes LL, Wilson RS, Schneider JA (2018) Religious orders study and rush memory and aging project. *J Alzheimers Dis* 64:S161–S189. <https://doi.org/10.3233/JAD-179939>
8. Bennett DA, Schneider JA, Arvanitakis Z, Wilson RS (2012) Overview and findings from the religious orders study. *Curr Alzheimer Res* 9:628–645. <https://doi.org/10.2174/15672051201322573>

9. Bennett DA, Schneider JA, Buchman AS, Barnes LL, Boyle PA, Wilson RS (2012) Overview and findings from the rush Memory and Aging Project. *Curr Alzheimer Res* 9:646–663. <https://doi.org/10.2174/156720512801322663>
10. Benveniste H, Liu X, Koundal S, Sanggaard S, Lee H, Wardlaw J (2019) The glymphatic system and waste clearance with brain aging: a review. *Gerontology* 65:106–119. <https://doi.org/10.1159/000490349>
11. Bhattarai P, Cosacak MI, Mashkaryan V, Demir S, Popova S, Govindarajan N et al (2020) Neuron-glia interaction through Serotonin-BDNF-NGFR axis enables regenerative neurogenesis in Alzheimer's model of adult zebrafish brain. *PLoS Biol* 18:e3000585. <https://doi.org/10.1371/journal.pbio.3000585>
12. Bhattarai P, Thomas AK, Cosacak MI, Papadimitriou C, Mashkaryan V, Zhang Y et al (2017) Modeling amyloid- β 42 toxicity and neurodegeneration in adult zebrafish brain. *J Vis Exp*. <https://doi.org/10.3791/56014>
13. Bhattarai P, Thomas AK, Papadimitriou C, Cosacak MI, Mashkaryan V, Froc C et al (2016) IL4/STAT6 signaling activates neural stem cell proliferation and neurogenesis upon Amyloid- β 42 aggregation in adult zebrafish brain. *Cell Rep* 17:941–948. <https://doi.org/10.1016/j.celrep.2016.09.075>
14. Bhattarai P, Thomas AK, Zhang Y, Kizil C (2017) The effects of aging on Amyloid- β 42-induced neurodegeneration and regeneration in adult zebrafish brain. *Neurogenesis* 4:e1322666. <https://doi.org/10.1080/23262133.2017.1322666>
15. Bis JC, Jian X, Kunkle BW, Chen Y, Hamilton-Nelson KL, Bush WS et al (2018) Whole exome sequencing study identifies novel rare and common Alzheimer's-Associated variants involved in immune response and transcriptional regulation. *Mol Psychiatry*. <https://doi.org/10.1038/s41380-018-0112-7>
16. Brenowitz WD, Keene CD, Hawes SE, Hubbard RA, Longstreth WT Jr, Woltjer RL et al (2017) Alzheimer's disease neuropathologic change, Lewy body disease, and vascular brain injury in clinic- and community-based samples. *Neurobiol Aging* 53:83–92. <https://doi.org/10.1016/j.neurobiolaging.2017.01.017>
17. Broce IJ, Tan CH, Fan CC, Jansen I, Savage JE, Witoelar A et al (2019) Dissecting the genetic relationship between cardiovascular risk factors and Alzheimer's disease. *Acta Neuropathol* 137:209–226. <https://doi.org/10.1007/s00401-018-1928-6>
18. Bush TG, Puvanachandra N, Horner CH, Polito A, Ostenfeld T, Svendsen CN et al (1999) Leukocyte infiltration, neuronal degeneration, and neurite outgrowth after ablation of scar-forming, reactive astrocytes in adult transgenic mice. *Neuron* 23:297–308. [https://doi.org/10.1016/s0896-6273\(00\)80781-3](https://doi.org/10.1016/s0896-6273(00)80781-3)
19. Cambroner FE, Liu D, Neal JE, Moore EE, Gifford KA, Terry JG et al (2018) APOE genotype modifies the association between central arterial stiffening and cognition in older adults. *Neurobiol Aging* 67:120–127. <https://doi.org/10.1016/j.neurobiolaging.2018.02.009>
20. Yang T, Chen H, Tang H, Li D, Wei P (2019) A powerful and data-adaptive test for rare-variant-based gene-environment interaction analysis. *Stat Med* 38:1230–1244. <https://doi.org/10.1002/sim.8037>
21. Chen X, Liu X, Koundal S, Elkin R, Zhu X, Monte B et al (2022) Cerebral amyloid angiopathy is associated with glymphatic transport reduction and time-delayed solute drainage along the neck arteries. *Nat Aging* 2:214–223. <https://doi.org/10.1038/s43587-022-00181-4>
22. Cheng D, Noble J, Tang MX, Schupf N, Mayeux R, Luchsinger JA (2011) Type 2 diabetes and late-onset Alzheimer's disease. *Dement Geriatr Cogn Disord* 31:424–430. <https://doi.org/10.1159/000324134>
23. Cole JW, Stine OC, Liu X, Pratap A, Cheng Y, Tallon LJ et al (2012) Rare variants in ischemic stroke: an exome pilot study. *PLoS ONE* 7:e35591. <https://doi.org/10.1371/journal.pone.0035591>
24. Cosacak MI, Bhattarai P, Reinhardt S, Petzold A, Dahl A, Zhang Y et al (2019) Single-cell transcriptomics analyses of neural stem cell heterogeneity and contextual plasticity in a zebrafish brain model of amyloid toxicity. *Cell Rep* 27(1307–1318):e1303. <https://doi.org/10.1016/j.celrep.2019.03.090>
25. Daneman R, Prat A (2015) The blood-brain barrier. *Cold Spring Harb Perspect Biol* 7:a020412. <https://doi.org/10.1101/cshperspect.a020412>
26. Das S, Forer L, Schönherr S, Sidore C, Locke AE, Kwong A et al (2016) Next-generation genotype imputation service and methods. *Nat Genet* 48:1284–1287. <https://doi.org/10.1038/ng.3656>
27. De Jager PL, Ma Y, McCabe C, Xu J, Vardarajan BN, Felsky D et al (2018) A multi-omic atlas of the human frontal cortex for aging and Alzheimer's disease research. *Sci Data* 5:180142. <https://doi.org/10.1038/sdata.2018.142>
28. Delaneau O, Zagury JF, Marchini J (2013) Improved whole-chromosome phasing for disease and population genetic studies. *Nat Methods* 10:5–6. <https://doi.org/10.1038/nmeth.2307>
29. Duncombe J, Kitamura A, Hase Y, Ihara M, Kalaria RN, Horsburgh K (2017) Chronic cerebral hypoperfusion: a key mechanism leading to vascular cognitive impairment and dementia. Closing the translational gap between rodent models and human vascular cognitive impairment and dementia. *Clin Sci (Lond)* 131:2451–2468. <https://doi.org/10.1042/CS20160727>
30. Faix J, Grosse R (2006) Staying in shape with formins. *Dev Cell* 10:693–706. <https://doi.org/10.1016/j.devcel.2006.05.001>
31. Farfel JM, Yu L, Buchman AS, Schneider JA, De Jager PL, Bennett DA (2016) Relation of genomic variants for Alzheimer disease dementia to common neuropathologies. *Neurology* 87:489–496. <https://doi.org/10.1212/WNL.0000000000002909>
32. Geisler R, Borel N, Ferg M, Maier JV, Strahle U (2016) Maintenance of zebrafish lines at the European Zebrafish Resource Center. *Zebrafish* 13(Suppl 1):S19–23. <https://doi.org/10.1089/zeb.2015.1205>
33. Gustafson D, Rothenberg E, Blennow K, Steen B, Skoog I (2003) An 18-year follow-up of overweight and risk of Alzheimer disease. *Arch Intern Med* 163:1524–1528. <https://doi.org/10.1001/archinte.163.13.1524>
34. Hecht M, Kramer LM, von Arnim CAF, Otto M, Thal DR (2018) Capillary cerebral amyloid angiopathy in Alzheimer's disease: association with allocortical/hippocampal microinfarcts and cognitive decline. *Acta Neuropathol* 135:681–694. <https://doi.org/10.1007/s00401-018-1834-y>
35. Hohman TJ, Cooke-Bailey JN, Reitz C, Jun G, Naj A, Beecham GW et al (2016) Global and local ancestry in African-Americans: implications for Alzheimer's disease risk. *Alzheimers Dement* 12:233–243. <https://doi.org/10.1016/j.jalz.2015.02.012>
36. Hudson LC, Bragg DC, Tompkins MB, Meeker RB (2005) Astrocytes and microglia differentially regulate trafficking of lymphocyte subsets across brain endothelial cells. *Brain Res* 1058:148–160. <https://doi.org/10.1016/j.brainres.2005.07.071>
37. Ís O, Wang X, Patel T, Quicksall Z, Heckman M, White L et al (2022) Single nuclei transcriptome reveals perturbed brain vascular molecules in Alzheimer's disease. *BioRxiv*, City
38. Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB et al (2018) NIA-AA research framework: toward a biological definition of Alzheimer's disease. *Alzheimers Dement* 14:535–562. <https://doi.org/10.1016/j.jalz.2018.02.018>
39. Janus C, Flores AY, Xu G, Borchelt DR (2015) Behavioral abnormalities in APPSwe/PS1dE9 mouse model of AD-like pathology: comparative analysis across multiple behavioral domains. *Neurobiol Aging* 36:2519–2532. <https://doi.org/10.1016/j.neurobiolaging.2015.05.010>

40. Jin SW, Beis D, Mitchell T, Chen JN, Stainier DY (2005) Cellular and molecular analyses of vascular tube and lumen formation in zebrafish. *Development* 132:5199–5209. <https://doi.org/10.1242/dev.02087>
41. Jun G, Ibrahim-Verbaas CA, Vronskaya M, Lambert JC, Chung J, Naj AC et al (2016) A novel Alzheimer disease locus located near the gene encoding tau protein. *Mol Psychiatry* 21:108–117. <https://doi.org/10.1038/mp.2015.23>
42. Justin BN, Turek M, Hakim AM (2013) Heart disease as a risk factor for dementia. *Clin Epidemiol* 5:135–145. <https://doi.org/10.2147/CLEP.S30621>
43. Kage F, Steffen A, Ellinger A, Ranftler C, Gehre C, Brakebusch C et al (2017) FMNL2 and -3 regulate Golgi architecture and anterograde transport downstream of Cdc42. *Sci Rep* 7:9791. <https://doi.org/10.1038/s41598-017-09952-1>
44. Kapasi A, DeCarli C, Schneider JA (2017) Impact of multiple pathologies on the threshold for clinically overt dementia. *Acta Neuropathol* 134:171–186. <https://doi.org/10.1007/s00401-017-1717-7>
45. Kargman DE, Sacco RL, Boden-Albala B, Paik MC, Hauser WA, Shea S (1999) Validity of telephone interview data for vascular disease risk factors in a racially mixed urban community: the Northern Manhattan Stroke Study. *Neuroepidemiology* 18:174–184. <https://doi.org/10.1159/000026209>
46. Kim SH, Ahn JH, Yang H, Lee P, Koh GY, Jeong Y (2020) Cerebral amyloid angiopathy aggravates perivascular clearance impairment in an Alzheimer's disease mouse model. *Acta Neuropathol Commun* 8:181. <https://doi.org/10.1186/s40478-020-01042-0>
47. Kimbrough IF, Robel S, Roberson ED, Sontheimer H (2015) Vascular amyloidosis impairs the gliovascular unit in a mouse model of Alzheimer's disease. *Brain* 138:3716–3733. <https://doi.org/10.1093/brain/awv327>
48. Kizil C (2018) Mechanisms of pathology-induced neural stem cell plasticity and neural regeneration in adult zebrafish brain. *Curr Pathobiol Rep* 6:71–77. <https://doi.org/10.1007/s40139-018-0158-x>
49. Kizil C, Otto GW, Geisler R, Nusslein-Volhard C, Antos CL (2009) Simplex controls cell proliferation and gene transcription during zebrafish caudal fin regeneration. *Dev Biol* 325:329–340. <https://doi.org/10.1016/j.ydbio.2008.09.032>
50. Kizil C, Sariya S, Kim YA, Rajabli F, Martin E, Reyes-Dumeyer D et al (2022) Admixture mapping of Alzheimer's disease in Caribbean Hispanics identifies a new locus on 22q13.1. *Mol Psychiatry*. <https://doi.org/10.1038/s41380-022-01526-6>
51. Kohler A, Collymore C, Finger-Baier K, Geisler R, Kaufmann L, Pounder KC et al (2017) Report of workshop on Euthanasia for zebrafish—a matter of welfare and science. *Zebrafish* 14:547–551. <https://doi.org/10.1089/zeb.2017.1508>
52. Kunkle BW, Grenier-Boley B, Sims R, Bis JC, Damotte V, Naj AC et al (2019) Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates A β , tau, immunity and lipid processing. *Nat Genet* 51:414–430. <https://doi.org/10.1038/s41588-019-0358-2>
53. Kunkle BW, Grenier-Boley B, Sims R, Bis JC, Damotte V, Naj AC et al (2019) Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Abeta, tau, immunity and lipid processing. *Nat Genet* 51:414–430. <https://doi.org/10.1038/s41588-019-0358-2>
54. Lambert JC, Grenier-Boley B, Harold D, Zelenika D, Chouraki V, Kamatani Y et al (2013) Genome-wide haplotype association study identifies the FRMD4A gene as a risk locus for Alzheimer's disease. *Mol Psychiatry* 18:461–470. <https://doi.org/10.1038/mp.2012.14>
55. Lathe R, Saponova A, Kotelevtsev Y (2014) Atherosclerosis and Alzheimer—diseases with a common cause? Inflammation, oxysterols, vasculature. *BMC Geriatr* 14:36. <https://doi.org/10.1186/1471-2318-14-36>
56. Lin X, Lee S, Christiani DC, Lin X (2013) Test for interactions between a genetic marker set and environment in generalized linear models. *Biostatistics* 14:667–681. <https://doi.org/10.1093/biostatistics/kxt006>
57. Luchsinger JA, Cheng D, Tang MX, Schupf N, Mayeux R (2012) Central obesity in the elderly is related to late-onset Alzheimer disease. *Alzheimer Dis Assoc Disord* 26:101–105. <https://doi.org/10.1097/WAD.0b013e318222f0d4>
58. Luchsinger JA, Reitz C, Honig LS, Tang MX, Shea S, Mayeux R (2005) Aggregation of vascular risk factors and risk of incident Alzheimer disease. *Neurology* 65:545–551. <https://doi.org/10.1212/01.wnl.0000172914.08967.dc>
59. Luchsinger JA, Tang MX, Stern Y, Shea S, Mayeux R (2001) Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. *Am J Epidemiol* 154:635–641. <https://doi.org/10.1093/aje/k154.7.635>
60. Manichaikul A, Mychaleckyj JC, Rich SS, Daly K, Sale M, Chen WM (2010) Robust relationship inference in genome-wide association studies. *Bioinformatics* (Oxford, England) 26:2867–2873. <https://doi.org/10.1093/bioinformatics/btq559>
61. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH et al (2011) The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement* 7:263–269. <https://doi.org/10.1016/j.jalz.2011.03.005>
62. Mills WA 3rd, Woo AM, Jiang S, Martin J, Surendran D, Bergstresser M et al (2022) Astrocyte plasticity in mice ensures continued endfoot coverage of cerebral blood vessels following injury and declines with age. *Nat Commun* 13:1794. <https://doi.org/10.1038/s41467-022-29475-2>
63. Nixon RA, Yang DS (2011) Autophagy failure in Alzheimer's disease—locating the primary defect. *Neurobiol Dis* 43:38–45. <https://doi.org/10.1016/j.nbd.2011.01.021>
64. Nourhashemi F, Deschamps V, Larrieu S, Letenneur L, Dartigues JF, Barberger-Gateau P et al (2003) Body mass index and incidence of dementia: the PAQUID study. *Neurology* 60:117–119. <https://doi.org/10.1212/01.wnl.0000038910.46217.aa>
65. Ott A, Breteler MM, de Bruyne MC, van Harskamp F, Grobbee DE, Hofman A (1997) Atrial fibrillation and dementia in a population-based study. *The Rotterdam Study*. *Stroke* 28:316–321. <https://doi.org/10.1161/01.str.28.2.316>
66. Papadimitriou C, Celikkaya H, Cosacak MI, Mashkaryan V, Bray L, Bhattarai P et al (2018) 3D culture method for Alzheimer's disease modeling reveals interleukin-4 rescues Abeta42-induced loss of human neural stem cell plasticity. *Dev Cell* 46(85–101):e108. <https://doi.org/10.1016/j.devcel.2018.06.005>
67. Pascale CL, Miller MC, Chiu C, Boylan M, Caralopoulos IN, Gonzalez L et al (2011) Amyloid-beta transporter expression at the blood-CSF barrier is age-dependent. *Fluids Barr CNS* 8:21. <https://doi.org/10.1186/2045-8118-8-21>
68. Qu X, Yuan FN, Corona C, Pasini S, Pero ME, Gundersen GG et al (2017) Stabilization of dynamic microtubules by mDia1 drives Tau-dependent Abeta1-42 synaptotoxicity. *J Cell Biol* 216:3161–3178. <https://doi.org/10.1083/jcb.201701045>
69. Reinhardt L, Kordes S, Reinhardt P, Glatza M, Baumann M, Drexler HCA et al (2019) Dual inhibition of GSK3beta and CDK5 protects the cytoskeleton of neurons from neuroinflammatory-mediated degeneration in vitro and in vivo. *Stem Cell Rep* 12:502–517. <https://doi.org/10.1016/j.stemcr.2019.01.015>
70. Reitz C, Tang MX, Schupf N, Manly JJ, Mayeux R, Luchsinger JA (2010) A summary risk score for the prediction of Alzheimer disease in elderly persons. *Arch Neurol* 67:835–841. <https://doi.org/10.1001/archneurol.2010.136>

71. Rojano E, Seoane P, Ranea JAG, Perkins JR (2019) Regulatory variants: from detection to predicting impact. *Brief Bioinform* 20:1639–1654. <https://doi.org/10.1093/bib/bby039>
72. Rose AB (2018) Introns as gene regulators: a brick on the accelerator. *Front Genet* 9:672. <https://doi.org/10.3389/fgene.2018.00672>
73. Salminen A, Kauppinen A, Kaarniranta K (2017) Hypoxia/ischemia activate processing of amyloid precursor protein: impact of vascular dysfunction in the pathogenesis of Alzheimer's disease. *J Neurochem* 140:536–549. <https://doi.org/10.1111/jnc.13932>
74. Schneider JA, Arvanitakis Z, Bang W, Bennett DA (2007) Mixed brain pathologies account for most dementia cases in community-dwelling older persons. *Neurology* 69:2197–2204. <https://doi.org/10.1212/01.wnl.0000271090.28148.24>
75. Schneider JA, Bienias JL, Wilson RS, Berry-Kravis E, Evans DA, Bennett DA (2005) The apolipoprotein E epsilon4 allele increases the odds of chronic cerebral infarction [corrected] detected at autopsy in older persons. *Stroke* 36:954–959. <https://doi.org/10.1161/01.STR.0000160747.27470.2a>
76. Shokri-Kojori E, Wang GJ, Wiers CE, Demiral SB, Guo M, Kim SW et al (2018) beta-Amyloid accumulation in the human brain after one night of sleep deprivation. *Proc Natl Acad Sci USA* 115:4483–4488. <https://doi.org/10.1073/pnas.1721694115>
77. Siddiqui T, Bhattarai P, Popova S, Cosacak MI, Sariya S, Zhang Y et al (2021) KYNA/Ahr signaling suppresses neural stem cell plasticity and neurogenesis in adult zebrafish model of Alzheimer's disease. *Cells*. <https://doi.org/10.3390/cells10102748>
78. Skoog I, Lernfelt B, Landahl S, Palmertz B, Andreasson LA, Nilsson L et al (1996) 15-year longitudinal study of blood pressure and dementia. *Lancet* 347:1141–1145. [https://doi.org/10.1016/s0140-6736\(96\)90608-x](https://doi.org/10.1016/s0140-6736(96)90608-x)
79. Strahle U, Scholz S, Geisler R, Greiner P, Hollert H, Rastegar S et al (2012) Zebrafish embryos as an alternative to animal experiments—a commentary on the definition of the onset of protected life stages in animal welfare regulations. *Reprod Toxicol* 33:128–132. <https://doi.org/10.1016/j.reprotox.2011.06.121>
80. Sun X, He G, Qing H, Zhou W, Dobie F, Cai F et al (2006) Hypoxia facilitates Alzheimer's disease pathogenesis by up-regulating BACE1 gene expression. *Proc Natl Acad Sci USA* 103:18727–18732. <https://doi.org/10.1073/pnas.0606298103>
81. Sun Z (2015) Aging, arterial stiffness, and hypertension. *Hypertension* 65:252–256. <https://doi.org/10.1161/HYPERTENSI.0NAHA.114.03617>
82. Sweeney MD, Sagare AP, Zlokovic BV (2018) Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. *Nat Rev Neurol* 14:133–150. <https://doi.org/10.1038/nrneurol.2017.188>
83. Tang MX, Stern Y, Marder K, Bell K, Gurland B, Lantigua R et al (1998) The APOE-epsilon4 allele and the risk of Alzheimer disease among African Americans, whites, and Hispanics. *JAMA* 279:751–755. <https://doi.org/10.1001/jama.279.10.751>
84. Tarasoff-Conway JM, Carare RO, Osorio RS, Glodzik L, Butler T, Fieremans E et al (2015) Clearance systems in the brain: implications for Alzheimer disease. *Nat Rev Neurol* 11:457–470. <https://doi.org/10.1038/nrneurol.2015.119>
85. Tingley D, Yamamoto T, Hirose K, Imai K, Keele L (2014) Mediation: R package for causal mediation analysis. *J Stat Softw* 59:1–38
86. Tosto G, Bird TD, Bennett DA, Boeve BF, Brickman AM, Cruchaga C et al (2016) The role of cardiovascular risk factors and stroke in familial Alzheimer disease. *JAMA Neurol* 73:1231–1237. <https://doi.org/10.1001/jamaneurol.2016.2539>
87. Toth P, Tarantini S, Csiszar A, Ungvari Z (2017) Functional vascular contributions to cognitive impairment and dementia: mechanisms and consequences of cerebral autoregulatory dysfunction, endothelial impairment, and neurovascular uncoupling in aging. *Am J Physiol Heart Circ Physiol* 312:H1–H20. <https://doi.org/10.1152/ajpheart.00581.2016>
88. Traylor M, Adib-Samii P, Harold D, Alzheimer's Disease Neuroimaging I, International Stroke Genetics Consortium UKYLS-DNAr, Dichgans M, Williams J, Lewis CM, Markus HS, Metastroke et al (2016) Shared genetic contribution to ischaemic stroke and Alzheimer's disease. *Ann Neurol* 79:739–747. <https://doi.org/10.1002/ana.24621>
89. van Sloten TT, Sedaghat S, Carnethon MR, Launer LJ, Stehouwer CDA (2020) Cerebral microvascular complications of type 2 diabetes: stroke, cognitive dysfunction, and depression. *Lancet Diabetes Endocrinol* 8:325–336. [https://doi.org/10.1016/S2213-8587\(19\)30405-X](https://doi.org/10.1016/S2213-8587(19)30405-X)
90. Vardarajan BN, Faber KM, Bird TD, Bennett DA, Rosenberg R, Boeve BF et al (2014) Age-specific incidence rates for dementia and Alzheimer disease in NIA-LOAD/NCRAD and EFIGA families: National Institute on Aging Genetics Initiative for Late-Onset Alzheimer Disease/National Cell Repository for Alzheimer Disease (NIA-LOAD/NCRAD) and Estudio Familiar de Influencia Genética en Alzheimer (EFIGA). *JAMA Neurol* 71:315–323. <https://doi.org/10.1001/jamaneurol.2013.5570>
91. Wakayama Y, Fukuhara S, Ando K, Matsuda M, Mochizuki N (2015) Cdc42 mediates Bmp-induced sprouting angiogenesis through Fmnl3-driven assembly of endothelial filopodia in zebrafish. *Dev Cell* 32:109–122. <https://doi.org/10.1016/j.devcel.2014.11.024>
92. Waldvogel HJ, Curtis MA, Baer K, Rees MI, Faull RL (2006) Immunohistochemical staining of post-mortem adult human brain sections. *Nat Protoc* 1:2719–2732. <https://doi.org/10.1038/nprot.2006.354>
93. Wan YW, Al-Ouran R, Mangleburg CG, Perumal TM, Lee TV, Allison K et al (2020) Meta-analysis of the alzheimer's disease human brain transcriptome and functional dissection in mouse models. *Cell Rep* 32:107908. <https://doi.org/10.1016/j.celrep.2020.107908>
94. Wang M, Beckmann ND, Roussos P, Wang E, Zhou X, Wang Q et al (2018) The Mount Sinai cohort of large-scale genomic, transcriptomic and proteomic data in Alzheimer's disease. *Sci Data* 5:180185. <https://doi.org/10.1038/sdata.2018.185>
95. Weng PH, Chen JH, Chen TF, Sun Y, Wen LL, Yip PK et al (2016) CHRNA7 polymorphisms and dementia risk: interactions with apolipoprotein epsilon4 and cigarette smoking. *Sci Rep* 6:27231. <https://doi.org/10.1038/srep27231>
96. Willer CJ, Li Y, Abecasis GR (2010) METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics (Oxford, England)* 26:2190–2191. <https://doi.org/10.1093/bioinformatics/btq340>
97. Wojtas AM, Kang SS, Olley BM, Gatherer M, Shinohara M, Lozano PA et al (2017) Loss of clusterin shifts amyloid deposition to the cerebrovasculature via disruption of perivascular drainage pathways. *Proc Natl Acad Sci USA* 114:E6962–E6971. <https://doi.org/10.1073/pnas.1701137114>
98. Xie L, Kang H, Xu Q, Chen MJ, Liao Y, Thiyagarajan M et al (2013) Sleep drives metabolite clearance from the adult brain. *Science* 342:373–377. <https://doi.org/10.1126/science.1241224>
99. Yamazaki Y, Kanekiyo T (2017) Blood-brain barrier dysfunction and the pathogenesis of Alzheimer's disease. *Int J Mol Sci*. <https://doi.org/10.3390/ijms18091965>
100. Yeo SY, Kim M, Kim HS, Huh TL, Chitnis AB (2007) Fluorescent protein expression driven by her4 regulatory elements reveals the spatiotemporal pattern of Notch signaling in the nervous system of zebrafish embryos. *Dev Biol* 301:555–567. <https://doi.org/10.1016/j.ydbio.2006.10.020>
101. Yu L, Tasaki S, Schneider JA, Arfanakis K, Duong DM, Wingo AP et al (2020) Cortical proteins associated with cognitive

resilience in community-dwelling older persons. *JAMA Psychiatry* 77:1172–1180. <https://doi.org/10.1001/jamapsychiatry.2020.1807>

102. Zenaro E, Piacentino G, Constantin G (2017) The blood–brain barrier in Alzheimer’s disease. *Neurobiol Dis* 107:41–56. <https://doi.org/10.1016/j.nbd.2016.07.007>

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Authors and Affiliations

Annie J. Lee^{1,2,3} · Neha S. Raghavan^{1,3} · Prabesh Bhattarai^{1,3,4} · Tohid Siddiqui⁴ · Sanjeev Sariya^{1,3} · Dolly Reyes-Dumeyer^{1,2,3} · Xena E. Flowers¹ · Sarah A. L. Cardoso¹ · Philip L. De Jager^{1,3} · David A. Bennett⁵ · Julie A. Schneider⁵ · Vilas Menon^{1,3} · Yanling Wang⁵ · Rafael A. Lantigua^{1,6} · Martin Medrano¹⁰ · Diones Rivera^{11,12} · Ivonne Z. Jiménez-Velázquez⁹ · Walter A. Kukull⁸ · Adam M. Brickman^{1,2,3} · Jennifer J. Manly^{1,2,3} · Giuseppe Tosto^{1,2,3} · Caghan Kizil^{1,3,4} · Badri N. Vardarajan^{1,2,3} · Richard Mayeux^{1,2,3,7}

¹ Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, College of Physicians and Surgeons, Columbia University, 630 West 168th Street, New York, NY 10032, USA

² The Gertrude H. Sergievsky Center, College of Physicians and Surgeons, Columbia University, 630 West 168th Street, New York, NY 10032, USA

³ Department of Neurology, College of Physicians and Surgeons, Columbia University and the New York Presbyterian Hospital, 710 West 168th Street, New York, NY 10032, USA

⁴ German Center for Neurodegenerative Diseases (DZNE), Helmholtz Association, Tatzberg 41, 01307 Dresden, Germany

⁵ Rush Alzheimer’s Disease Center, Rush University Medical Center, Chicago, IL 60612, USA

⁶ Department of Medicine, College of Physicians and Surgeons, Columbia University, and the New York Presbyterian Hospital, 630 West 168th Street, New York, NY 10032, USA

⁷ Department of Psychiatry, College of Physicians and Surgeons, Columbia University, 1051 Riverside Drive, New York, NY 10032, USA

⁸ Department of Epidemiology, School of Public Health, University of Washington, Seattle, WA 98195, USA

⁹ Department of Medicine, Medical Sciences Campus, University of Puerto Rico School of Medicine, San Juan, Puerto Rico 00936, USA

¹⁰ School of Medicine, Pontificia Universidad Católica Madre y Maestra (PUCMM), Santiago, Dominican Republic

¹¹ Department of Neurology, CEDIMAT, Plaza de la Salud, Santo Domingo, Dominican Republic

¹² School of Medicine, Universidad Pedro Henríquez Ureña (UNPHU), Santo Domingo, Dominican Republic